Melanoma News and reporting on melanoma. DermTech Q1 Revenues up 62 Percent The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020. Castle Biosciences Q1 Revenues Up 31 Percent The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent. Castle Biosciences Q4 Revenues Down 2 Percent The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter. Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes. DermTech Using $144M Financing to Spur Marketing, Telemedicine Efforts For Molecular Melanoma Assay Premium The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer. Jan 22, 2021 Oppenheimer Initiates Coverage of DermTech With Outperform Rating Jan 19, 2021 OncoHost Raises $8 Million in Series B Funding Round Dec 23, 2020 Personalis Sees New Neoantigen Platform Driving Improved Immunotherapy Prediction Premium Dec 14, 2020 Craig-Hallum Initiates Coverage of DermTech With Buy Rating Dec 10, 2020 Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression Dec 3, 2020 Local Coverage Determinations Roundup: Castle Bio Nov 18, 2020 IsoPlexis Targets New Market Segments With Cheaper, More Flexible Single-Cell Proteomic Systems Premium Nov 16, 2020 Somatic Mutations in Lung Cancer Patients With HLA Supertype B44 Influence Immunotherapy Response Nov 9, 2020 Castle Biosciences Q3 Revenues Up 3 Percent Nov 6, 2020 Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests Oct 23, 2020 Melanoma Treatment Stage Affects Ability of Liquid Biopsy to Predict Immunotherapy Benefit Premium Oct 22, 2020 Local Coverage Determinations Roundup: CareDx, Castle Bio, Decipher Biosciences Oct 8, 2020 Castle Bio Receives Expanded Medicare Coverage for Melanoma Test Oct 7, 2020 Post-mortem Melanocyte Mutations Provide Melanoma Clues Sep 23, 2020 Pale Melanoma Susceptibility Linked to Albinism-Related Genes Sep 10, 2020 Cowen Initiates Coverage of DermTech With Outperform Rating Aug 19, 2020 Antegenes Receives CE Marks for Cancer, Melanoma Polygenic Risk Score Tests Aug 10, 2020 Castle Biosciences Q2 Revenues Up 18 Percent Jul 30, 2020 Heritable Gene Expression in Single Cells Leads to Subpopulations With Marked Behaviors Jul 27, 2020 Oncology Informatics Firm Vidence Emerges to Supply Real-World Clinical, Genomic Data to Researchers Premium Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.